Moderna has announced it will submit an Emergency Use Authorization request to the US FDA today for its COVID-19 vaccine candidate. It has also released the Phase 3 primary efficacy analysis, showing 94.1% efficacy.
BioNTech & InstaDeep launch AI innovation lab for next-generation vaccines and biopharmaceuticals
COVID-19
BioInvent inks antibody manufacturing agreement with Cantargia
Pipelines
Compulsory licensing is not an effective policy tool, warns EU biopharma group as it reacts to European IP action plan
COVID-19
New EU pharma strategy looks to future-proof healthcare sector, stimulate innovation and boost access to biosimilars and generics
Biosimilars
